Methods and materials for assessing prostate cancer therapies

Details Methods and materials for assessing prostate cancer therapies Methods and materials for assessing prostate cancer therapies

2004-12-16

2011-10-11

Aeder, Sean (Department: 1642)

Chemistry: molecular biology and microbiology

Measuring or testing process involving enzymes or...

Reexamination Certificate

active

08034548

ABSTRACT:
Using microarray-based profiling of isogenic prostate cancer xenograft models, we found that a modest (2-5 fold) increase in androgen receptor (AR) mRNA was the only expression change consistently associated with developing resistance to antiandrogen therapy. Increased levels of AR confer resistance to anti-androgens by amplifying signal output from low levels of residual ligand and altering the normal response to antagonists. This invention provides cell based assays for use in the examination of new therapeutic modalities and provides insight toward the design of novel antiandrogens.

REFERENCES:
patent: 3984430 (1976-10-01), Curran
patent: 4097578 (1978-06-01), Perronnet et al.
patent: 4234736 (1980-11-01), Bernauer et al.
patent: 4304782 (1981-12-01), Dumont et al.
patent: 4312881 (1982-01-01), Wootton
patent: 4399216 (1983-08-01), Axel et al.
patent: 4407814 (1983-10-01), Bernauer et al.
patent: 4482739 (1984-11-01), Bernauer et al.
patent: 4559157 (1985-12-01), Smith et al.
patent: 4608392 (1986-08-01), Jacquet et al.
patent: 4820508 (1989-04-01), Wortzman
patent: 4873256 (1989-10-01), Coussediere et al.
patent: 4938949 (1990-07-01), Borch et al.
patent: 4992478 (1991-02-01), Geria
patent: 5010182 (1991-04-01), Brake et al.
patent: 5071773 (1991-12-01), Evans et al.
patent: 5166358 (1992-11-01), Seuron et al.
patent: 5411981 (1995-05-01), Gaillard-Kelly et al.
patent: 5434176 (1995-07-01), Claussner et al.
patent: 5556983 (1996-09-01), Claussner et al.
patent: 5589497 (1996-12-01), Claussner et al.
patent: 5614620 (1997-03-01), Liao et al.
patent: 5627201 (1997-05-01), Gaillard-Kelly et al.
patent: 5646172 (1997-07-01), Claussner et al.
patent: 5656651 (1997-08-01), Sovak et al.
patent: 5705654 (1998-01-01), Claussner et al.
patent: 5726061 (1998-03-01), Robbins et al.
patent: 5750553 (1998-05-01), Claussner et al.
patent: RE35956 (1998-11-01), Gaillard-Kelly et al.
patent: 5958936 (1999-09-01), Claussner et al.
patent: 5985868 (1999-11-01), Gray
patent: 6087509 (2000-07-01), Claussner et al.
patent: 6107488 (2000-08-01), Bouchet et al.
patent: 6242611 (2001-06-01), Claussner et al.
patent: 6307030 (2001-10-01), French et al.
patent: 6472415 (2002-10-01), Sovak et al.
patent: 6479063 (2002-11-01), Weisman et al.
patent: 6489163 (2002-12-01), Roy et al.
patent: 6506607 (2003-01-01), Shyjan
patent: 6828471 (2004-12-01), Sawyers et al.
patent: 7271188 (2007-09-01), Tachibana et al.
patent: 2002/0133833 (2002-09-01), Sawyers et al.
patent: 2004/0009969 (2004-01-01), Cleve et al.
patent: 2004/0116417 (2004-06-01), Boubia et al.
patent: 2005/0153968 (2005-07-01), Bi et al.
patent: 2006/0127902 (2006-06-01), Madden et al.
patent: 2007/0249697 (2007-10-01), Tachibana et al.
patent: 217893 (1958-06-01), None
patent: 0017976 (1980-10-01), None
patent: 0017976 (1980-10-01), None
patent: 0017976 (1983-06-01), None
patent: 0 002 259 (1984-10-01), None
patent: 0331232 (1989-09-01), None
patent: 362179 (1990-04-01), None
patent: 0 494 819 (1992-01-01), None
patent: 0 578 516 (1993-05-01), None
patent: 0 580 459 (1993-05-01), None
patent: 0 580 459 (1994-01-01), None
patent: 0 494 819 (1996-07-01), None
patent: 0 721 944 (2001-01-01), None
patent: 1 790 640 (2007-05-01), None
patent: 2 693 461 (1994-01-01), None
patent: 2 715 402 (1994-01-01), None
patent: 2 845 384 (2002-10-01), None
patent: 2019363 (1990-01-01), None
patent: WO 90/13646 (1990-11-01), None
patent: WO 97/00071 (1997-01-01), None
patent: WO 97/19064 (1997-06-01), None
patent: WO 97/19931 (1997-06-01), None
patent: WO 00/17163 (2000-03-01), None
patent: WO 02/053155 (2002-07-01), None
patent: WO 02/081453 (2002-10-01), None
patent: WO 03/029245 (2003-04-01), None
patent: WO03/057220 (2003-07-01), None
patent: WO 03/093243 (2003-11-01), None
patent: WO 03/096980 (2003-11-01), None
patent: WO 2004/031160 (2004-04-01), None
patent: WO 2004/070050 (2004-08-01), None
patent: WO 2005/059109 (2005-06-01), None
patent: WO2005/059109 (2005-06-01), None
patent: WO 2005/089752 (2005-09-01), None
patent: WO 2005/099693 (2005-10-01), None
patent: WO 2006/010642 (2006-02-01), None
patent: WO 2006/028226 (2006-03-01), None
patent: WO2005/059109 (2006-09-01), None
patent: WO 2006/124118 (2006-11-01), None
patent: WO 2007/126765 (2007-11-01), None
patent: WO 2007/127010 (2007-11-01), None
patent: WO 2008/119015 (2008-10-01), None
Burnstein et al (Molecular and Cellular Endocrinology, 1995, 115:177-186).
Cinar et al (Cancer Research, Oct. 2001, 61: 7310-7317).
Szelei et al (Endocrinology, 1997, 138(4): 1406-1412).
Raffo et al (Cancer Research, Oct. 1995, 4438-4445).
Burnstein et al (Molecular and Cellular Endocrinology, 1995, 115: 177-186).
Zajchowski et al (Cancer Research, 1993, 53: 5004-5011).
Wallen et al., “Androgen Receptor Gene Mutations in Hormone-Refractory Prostate Cancer”, J. Pathology 1999, vol. 189, pp. 559-563.
Lu et al., “Molecular Mechanisms of Androgen-Independent Growth of Human Prostate Cancer LNCaP-A1 Cells”, Endocrinology 1999, vol. 140, No. 11, pp. 5054-5059.
Karp et al., Cancer Res. 56: 5547-5556.
Ausubel et al., Current Protocols in Molecular Biology, Wiley Interscience Publishers, (1995).
Sambrook et al., Molecular Cloning: A Laboratory Manual 2ndedition (1989) Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y.
Chang et al., Science 240 (4850), 324-326 (1988).
NM—000044<http://www.ncbi.nlm.nih.gov:80/entrez/viewerfcgi?cmd=Retrieve&db=nucleotide&list—uids=21322251&dopt=GenBank&term=sapiens+AR+androgen+receptor+prostate+cancer&qty=1>gi:21322251, printed Oct. 24, 2007.
Mammalian Cell Biotechnology: a Practical Approach,M. Butler, ed. (IRL Press, 1991).
Graham and van der Eb,Virology,52:456-467.
Keown et al.,Methods in Enzymology,185:527-537 (1990).
Mansour et al.,Nature,336:348-352 (1988).
Muller et al., 1991, Mol. & Cell. Bio. 11:1785.
Urlaub et al.,Proc. Natl. Acad. Sci. USA,77:4216 (1980).
Stinchcomb et al.,Nature,282:39 (1979).
Kingsman et al.,Gene,7: 141 (1979).
Tschumper et al.,Gene,10: 157 (1980).
Jones,Genetics,85:12 (1977).
Feldman, B.J. & Feldman, D. The development of androgen-independent prostate cancer. Nat Rev Cancer 1, 34-45 (2001).
Gelmann, E.P. Molecular biology of the androgen receptor. J Clin Oncol 20, 3001-15 (2002).
Balk, S.P. Androgen receptor as a target in androgen-independent prostate cancer. Urology 60, 132-8; discussion 138-9 (2002).
Taplin, M.E. et al. Selection for androgen receptor mutations in prostate cancers treated with androgen antagonist. Cancer Res 59, 2511-5 (1999).
Taplin, M.E. et al. Androgen receptor mutations in androgen-independent prostate cancer: Cancer and Leukemia Group B Study 9663. J Clin Oncol 21, 2673-8 (2003).
Visakorpi, T. et al. In vivo amplification of the androgen receptor gene and progression of human prostate cancer. Nat Genet 9, 401-6 (1995).
Taplin, M.E. et al. Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer. N Engl J Med 332, 1393-8 (1995).
Veldscholte, J. et al. A mutation in the ligand binding domain of the androgen receptor of human LNCaP cells affects steroid binding characteristics and response to anti-androgens. Biochem Biophys Res Commun 173, 534-40 (1990).
Matias, P.M. et al. Structural basis for the glucocorticoid response in a mutant human androgen receptor (AR(ccr)) derived from an androgen-independent prostate cancer. J Med Chem 45, 1439-46 (2002).
Craft, N., Shostak, Y., Carey, M. & Sawyers, C.L. A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the HER-2
eu tyrosine kinase. Nat Med 5, 280-5 (1999).
Gioeli, D. et al. Androgen receptor phosphorylation. Regulation and identification of the phosphorylation sites. J Biol Chem 277, 29304-14 (2002).
Kato, S. et al. Activation of the estrogen receptor through phosphorylation by mitogen-activated protein kinase. Science 270, 1491-4 (1995).
Font de Mora, J. & Brown, M. AIB1 is a conduit for kinase-mediated growth factor signaling to the estrogen receptor. Mol Cell Biol 20, 5041-7 (2000).
Tremblay, A.,

Affiliated with

Also associated with

Rating

Methods and materials for assessing prostate cancer therapies does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Methods and materials for assessing prostate cancer therapies, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods and materials for assessing prostate cancer therapies will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4290024